Premium
The impact of frailty on treatment for overactive bladder in older adults
Author(s) -
Suskind Anne M.,
Kowalik Casey,
Quanstrom Kathryn,
Boscardin John,
Zhao Shoujun,
Reynolds W. Stuart,
Mishra Kavita,
Finlayson Emily
Publication year - 2019
Publication title -
neurourology and urodynamics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 90
eISSN - 1520-6777
pISSN - 0733-2467
DOI - 10.1002/nau.24093
Subject(s) - overactive bladder , medicine , gerontology , older people , urology , alternative medicine , pathology
Aims: To examine the impact of frailty on treatment outcomes for overactive bladder (OAB) in older adults starting pharmacotherapy, onabotulinumtoxinA, and sacral neuromodulation. Methods: This is a prospective study of men and women age ≥60 years starting pharmacotherapy, onabotulinumtoxinA, or sacral neuromodulation. Subjects were administered questionnaires at baseline and again at 1‐ and 3‐months. Frailty was assessed at baseline using the timed up and go test (TUGT), whereby a TUGT time of ≥12 seconds was considered to be slow, or frail. Response to treatment was assessed using the overactive bladder symptom score (OABSS) and the OAB‐q SF (both Bother and HRQOL subscales). Information on side effects/adverse events was also collected. Mixed effects linear modeling was used to model changes in outcomes over time both within and between groups. Results: A total of 45 subjects enrolled in the study, 40% (N = 18) of whom had a TUGT ≥12 seconds. Both TUGT groups demonstrated improvement in OAB symptoms over time and there were no statistically significant differences in these responses per group (all P ‐values >.05). Similar trends were found for both OAB‐q SF Bother and OAB‐q SF HRQOL questionnaire responses. Side effects and adverse events were not significantly different between groups (all P 's >.05). Conclusions: Adults ≥60 years of age starting second‐ and third‐line treatments for OAB, regardless of TUGT time, demonstrated improvement in OAB symptoms at 3 months. These findings suggest that frail older adults may receive comparable benefit and similar rates of side effects compared with less frail older individuals.